Retatrutide is like having three different weight loss coaches working together in your body at the same time. While most weight loss medications only target one or two pathways, this peptide hits three major systems that control how your body handles food and burns energy. People are excited about it because in clinical trials, participants lost an average of 24% of their body weight in less than a year — that's more dramatic than any weight loss drug we've ever seen.
Think of your metabolism like a three-part orchestra that's gotten out of sync. Retatrutide acts as a conductor that gets all three sections playing together again. First, it activates your GLP-1 receptors, which are like your body's natural appetite dimmer switch — they make you feel full faster and keep food in your stomach longer. Second, it triggers GIP receptors that help your pancreas work better and improve how your body processes fats. But here's where it gets really interesting: the third target, glucagon receptors, is like hitting the gas pedal on your metabolism. While the other two mechanisms help you eat less, glucagon actually makes your liver burn fat faster and cranks up your overall energy expenditure. It's this triple action — eating less plus burning more — that creates such powerful results.
Dosage Information
Typical Dose
1-12 mg weekly (Phase 2 trial doses)
Frequency
Once weekly
Administration
Subcutaneous injection
Half-Life
6 days
Notes
Currently in Phase 3 clinical trials. Not yet FDA approved. This entry documents the research context for this highly anticipated compound.
Why this matters
Triple agonist (GLP-1/GIP/glucagon) with long half-life; once-weekly dosing in trials.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
40
unit mark
Draw 40 units for your 1000mcg dose of Retatrutide
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Retatrutide sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.75
Compound Data
Molecular Formula
C221H342N46O68
Molecular Weight
4731.00 g/mol
IUPAC Name
20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
171390338Potential Side Effects
Retatrutide discussions
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1-12 mg weekly (Phase 2 trial doses)
- Frequency
- Once weekly
- References
- 0 curated + 43 from PubMed
- Clinical Trials
- 32 registered
- Evidence Score
- 0.8 / 100
Frequently Asked Questions about Retatrutide
What is Retatrutide?
Retatrutide is a first-in-class triple agonist targeting GIP GLP-1 and glucagon receptors simultaneously developed by Eli Lilly. Phase 2 trial data published in 2023 showed average weight loss of 24% of body weight at 48 weeks — the highest weight loss ever reported for a pharmacological intervention in a clinical trial. Retatrutide represents the frontier of metabolic peptide therapeutics combining three complementary receptor agonist mechanisms for unprecedented efficacy in obesity treatment.
How does Retatrutide work?
Retatrutide simultaneously activates three receptors involved in energy metabolism. GLP-1 receptor agonism provides incretin effects appetite suppression and gastric emptying delay. GIP receptor agonism complements GLP-1 signaling in the pancreas and adipose tissue improving insulin sensitivity and lipid metabolism. Glucagon receptor agonism adds a third mechanism — stimulating hepatic fat burning and increasing energy expenditure through thermogenic effects. The glucagon component is particularly important for differentiating retatrutide from dual GIP/GLP-1 agonists like tirzepatide — glucagon receptor activation directly increases metabolic rate and fat oxidation producing weight loss through both reduced intake and increased expenditure. The combination of all three mechanisms produces the remarkable efficacy observed in trials.
What is the recommended dosage for Retatrutide?
The typical dose is 1-12 mg weekly (Phase 2 trial doses). Once weekly. Administration: Subcutaneous injection. Currently in Phase 3 clinical trials. Not yet FDA approved. This entry documents the research context for this highly anticipated compound.
What are the side effects of Retatrutide?
Nausea (very common). Vomiting (common). Diarrhea (common). Decreased appetite (pronounced). Gallbladder issues with rapid weight loss (uncommon)
What is the Retatrutide cycle protocol?
Retatrutide is typically cycled ongoing. Once weekly subcutaneous injection, Phase 3 trials
Questions reflect common community inquiries. This is not medical advice.